Clinical Information
Gen. Code and Des.
76045 brimonidine tartrate TOPICAL GEL W/PUMP 0.33 %
GCN and Des.
41249 brimonidine tartrate TOPICAL GEL W/PUMP 0.33 %
Strength
0.33%
Dose Form
GEL WITH PUMP (GRAM)
Product Category
RX Pharmaceuticals
Fine Line Class
850085008510 All Rx Products
DEA Class
NC
OMP Family
AHFS Class
84920000 SKIN AND MUCOUS MEMBRANE AGENTS, MISC.
Active Ingredients
6197 brimonidine tartrate 70359465
Inactive Ingredients
2468 propylene glycol 57556
3141 benzalkonium chloride 8001545
MIRVASO - brimonidine tartrate gel
Galderma Laboratories, L.P.
1 INDICATIONS AND USAGE
MIRVASO (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.
2 DOSAGE AND ADMINISTRATION
Apply a pea-sized amount once daily to each of the five areas of the face: central forehead, chin, nose, each cheek. MIRVASO topical gel should be applied smoothly and evenly as a thin layer across the entire face avoiding the eyes and lips.
Wash hands after applying MIRVASO topical gel.
MIRVASO topical gel is for topical use only and not for oral, ophthalmic, or intravaginal use.
3 DOSAGE FORMS AND STRENGTHS
MIRVASO (brimonidine) topical gel, 0.33% is a white to light yellow opaque aqueous gel. Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.
4 CONTRAINDICATIONS
MIRVASO topical gel is contratindicated in patients who have experienced a hypersensitivity reaction to any component. Reactions have included angioedema, urticaria, and contact dermatitis [see Warnings and Precautions (5.6) and Adverse Reactions (6.1,6.2) ].
5 WARNINGS AND PRECAUTIONS
5.1 Potentiation of Vascular Insufficiency
MIRVASO topical gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sj�gren's syndrome.
5.2 Severe Cardiovascular Disease
Alpha-2 adrenergic agonists can lower blood pressure. MIRVASO topical gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease.
5.3 Serious Adverse Reactions Following Ingestion of MIRVASO topical gel
Two young children of a subject in a clinical trial experienced serious adverse reactions following accidental ingestion of MIRVASO topical gel. Adverse reactions experienced by one or both children included lethargy, respiratory distress with apneic episodes (requiring intubation), sinus bradycardia, confusion, psychomotor hyperactivity, and diaphoresis. Both children were hospitalized overnight and discharged the following day without sequelae.
Keep MIRVASO topical gel out of the reach of children.
5.4 Systemic Adverse Reactions of Alpha-2 Adrenergic Agonists
Postmarketing cases of bradycardia, hypotension (including orthostatic hypotension) and dizziness have been reported. Some cases required hospitalization. Some cases involved application of MIRVASO topical gel in unapproved dosing regimens and for unapproved indications, including the application of MIRVASO topical gel following laser procedures.
Avoid applying MIRVASO topical gel to irritated skin or open wounds.
5.5 Local Vasomotor Adverse Reactions
Erythema
Some subjects in the clinical trials discontinued use of MIRVASO topical gel because of erythema. Some subjects in the clinical trials reported a rebound phenomenon, where erythema was reported to return worse compared to the severity at baseline.
Erythema appeared to resolve after discontinuation of MIRVASO topical gel.[see Adverse Reactions (6.1) ].
The treatment effect of MIRVASO topical gel may begin to diminish hours after application.
From postmarketing reports, some patients have experienced erythema involving areas of the face that were previously not affected by erythema and in areas (e.g., neck and chest) outside of the treatment sites.
Flushing
Some subjects in the clinical trials discontinued use of MIRVASO topical gel because of flushing.
Intermittent flushing occurred in some subjects treated with MIRVASO topical gel in the clinical trials. The onset of flushing relative to application of MIRVASO topical gel varied, ranging from approximately 30 minutes to several hours [see Adverse Reactions (6.1) ]. Flushing appeared to resolve after discontinuation of MIRVASO topical gel.
From postmarketing reports, some patients have experienced increased frequency of flushing and/or increased depth of
erythema with the flushing. Additionally, some patients reported new onset of flushing.
Pallor and Excessive Whitening
From postmarketing reports, some patients have experienced pallor or excessive whitening at or outside the application site following treatment with MIRVASO topical gel.
5.6 Hypersensitivity
Allergic contact dermatitis was reported in the clinical trials for MIRVASO topical gel [see Adverse Reactions (6.1) ].
Events reported post marketing with the use of MIRVASO topical gel include angioedema, throat tightening, tongue swelling, and urticaria, [see Adverse Reactions (6.2) ]. Institute appropriate therapy and discontinue MIRVASO topical gel, if clinically significant hypersensitivity reaction occurs.
6 ADVERSE REACTIONS
The following adverse drug reactions are discussed in greater detail in other sections of the label:
Systemic Adverse Reactions of Alpha-2 Adrenergic Agonists [see Warnings and Precautions (5.4) ]
Local Vasomotor Adverse Reactions [see Warnings and Precautions (5.5) ]
Hypersensitivity [see Warnings and Precautions (5.6) ]
